Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 5/2019

01-05-2019 | Panitumumab | Colorectal Cancer

Prognostic Value of Primary Tumor Sidedness for Unresectable Stage IV Colorectal Cancer: A Retrospective Study

Authors: Dai Shida, MD, PhD, Taro Tanabe, MD, Narikazu Boku, MD, PhD, Atsuo Takashima, MD, Takefumi Yoshida, MD, PhD, Shunsuke Tsukamoto, MD, PhD, Yukihide Kanemitsu, MD

Published in: Annals of Surgical Oncology | Issue 5/2019

Login to get access

Abstract

Background

When treated with molecular targeted agents, patients with unresectable colorectal cancer with right-sided tumors have poorer prognoses than those with left-sided tumors. While primary tumor sidedness may have prognostic value, the prognostic value of tumor sidedness in chemotherapy regimens without targeted therapy is unclear.

Methods

Our study population comprised 678 consecutive patients with unresectable stage IV colorectal cancer who received systemic chemotherapy at the National Cancer Center Hospital in Japan from 1999 to 2015. Patients were stratified by treatment subgroup (with or without molecular targeted agents and with or without palliative primary tumor resection), and relationships between overall survival (OS) and primary tumor sidedness were evaluated. Multivariate analyses were also performed.

Results

Overall, 193 (28%) tumors were right-sided (cecum to transverse colon) and 485 (72%) were left-sided (splenic flexure to rectum). In the overall population, median survival time was 16.4 months for those with right-sided tumors and 23.4 months for those with left-sided tumors (p < 0.01). Regardless of the use or non-use of targeted agents and performance or non-performance of palliative resection of the primary tumor, those with right-sided tumors showed significantly poorer prognosis than those with left-sided tumors, in all categories. Multivariate analyses showed right-sided tumors to be associated with shorter OS compared with left-sided tumors (hazard ratio 1.26, 95% confidence interval 1.03–1.53; p =0.024).

Conclusion

Unresectable stage IV right-sided colorectal tumors were associated with shorter OS compared with left-sided tumors, regardless of treatment strategy. Primary tumor sidedness may be an independent prognostic factor.
Appendix
Available only for authorised users
Literature
1.
UICC. TNM classification of malignant tumours. 8th ed. New York: Wiley; 2017.
2.
Allegra CJ, Jessup JM, Somerfield MR, et al. American society of clinical oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009;27(12):2091–6.CrossRefPubMed
3.
Sinicrope FA, Shi Q, Smyrk TC, et al. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology. 2015;148(1):88–99.CrossRefPubMed
4.
Gavin PG, Colangelo LH, Fumagalli D, et al. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res. 2012;18(23):6531–41.CrossRefPubMedPubMedCentral
5.
Lee MS, Menter DG, Kopetz S. Right versus left colon cancer biology: integrating the consensus molecular subtypes. J Natl Compr Cancer Netw. 2017;15(3):411–9.CrossRef
6.
Arnold D, Lueza B, Douillard JY, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017;28(8):1713–29.CrossRefPubMedPubMedCentral
7.
8.
Loupakis F, Yang D, Yau L, et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst. 2015;107(3): pii: dju427.
9.
Shida D, Tsukamoto S, Ochiai H, Kanemitsu Y. long-term outcomes after R0 resection of synchronous peritoneal metastasis from colorectal cancer without cytoreductive surgery or hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2018;25(1):173–8.CrossRefPubMed
10.
Shida D, Yoshida T, Tanabe T, Tsukamoto S, Ochiai H, Kanemitsu Y. Prognostic impact of R0 resection and targeted therapy for colorectal cancer with synchronous peritoneal metastasis. Ann Surg Oncol. 2018;25(6):1646–53.CrossRefPubMed
11.
Cartwright TH, Yim YM, Yu E, Chung H, Halm M, Forsyth M. Survival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in US community oncology. Clin Colorectal Cancer. 2012;11(4):238–46.CrossRefPubMed
12.
Shida D, Hamaguchi T, Ochiai H, et al. Prognostic impact of palliative primary tumor resection for unresectable stage 4 colorectal cancer: using a propensity score analysis. Ann Surg Oncol. 2016;23(11):3602–8.CrossRefPubMed
13.
Shida D, Ochiai H, Tsukamoto S, Kanemitsu Y. Long-term outcomes of laparoscopic versus open D3 dissection for stage II/III colon cancer: results of propensity score analyses. Eur J Surg Oncol. 2018;44(7):1025–30.CrossRefPubMed
14.
Clark GM. Prognostic factors versus predictive factors: examples from a clinical trial of erlotinib. Mol Oncol. 2008;1(4):406-12.CrossRefPubMed
15.
Wallace K, DeToma A, Lewin DN, et al. Racial differences in stage IV colorectal cancer survival in younger and older patients. Clin Colorectal Cancer. 2017;16(3):178–86.CrossRefPubMed
16.
Shabihkhani M, Yu SS, Yang D, et al. Metastatic colorectal cancer in hispanics: treatment outcomes in a treated population. Clin Colorectal Cancer. 2016;15(4):e221–7.CrossRefPubMed
17.
Shida D, Ahiko Y, Tanabe T, et al. Shorter survival in adolescent and young adult patients, compared to adult patients, with stage IV colorectal cancer in Japan. BMC Cancer. 2018;18(1):334.CrossRefPubMedPubMedCentral
18.
O’Connell JB, Maggard MA, Liu JH, Etzioni DA, Livingston EH, Ko CY. Do young colon cancer patients have worse outcomes? World J Surg. 2004;28(6):558–62.CrossRefPubMed
19.
Azzoni C, Bottarelli L, Campanini N, et al. Distinct molecular patterns based on proximal and distal sporadic colorectal cancer: arguments for different mechanisms in the tumorigenesis. Int J Colorectal Dis. 2007;22(2):115–26.CrossRefPubMed
20.
21.
Watanabe T, Muro K, Ajioka Y, et al. Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol. 2018;23(1):1–34.CrossRefPubMed
Metadata
Title
Prognostic Value of Primary Tumor Sidedness for Unresectable Stage IV Colorectal Cancer: A Retrospective Study
Authors
Dai Shida, MD, PhD
Taro Tanabe, MD
Narikazu Boku, MD, PhD
Atsuo Takashima, MD
Takefumi Yoshida, MD, PhD
Shunsuke Tsukamoto, MD, PhD
Yukihide Kanemitsu, MD
Publication date
01-05-2019
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 5/2019
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07209-x

Other articles of this Issue 5/2019

Annals of Surgical Oncology 5/2019 Go to the issue

Pancreatic Tumors

Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer Potentially Improves Survival and Facilitates Surgery

Gastrointestinal Oncology

The Prognostic Value of a Pathologic Complete Response After Neoadjuvant Therapy for Digestive Cancer: Systematic Review and Meta-Analysis of 21 Studies

Thoracic Oncology

Is a Novel Nomogram Better Than TNM Staging at Predicting Survival in Siewert Type 2 Adenocarcinoma?

Breast Oncology

Reproductive Health Issues for Young Women with Breast Cancer: Emerging Strategies for Difficult Situations

Thoracic Oncology

Proposal of a Nomogram for Predicting Survival in Patients with Siewert Type II Adenocarcinoma of the Esophagogastric Junction After Preoperative Radiation

ASO Author Reflections

ASO Author Reflections: Challenges in the Management of Young Women with Breast Cancer—Fertility Preservation and Pregnancy